Every 10-Q that Design Therapeutics, Inc. (DSGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DSGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DSGN filings page.
Design Therapeutics is a clinical-stage biotech developing GeneTAC small-molecule therapies for repeat expansion diseases. For the quarter ended June 30, 2026, it reported a net loss of $20.2 million, or $0.32 per share, on operating expenses of $22.2 million. Cash, cash equivalents and investment securities totaled $207.4 million, and management expects this to fund operations for more than 12 months.
Lead FA candidate DT‑216P2 showed dose‑dependent FXN biomarker increases and clinical improvements in the RESTORE‑FA Phase 1/2 trial, with whole‑blood FXN mRNA up 65% at 1 mpk and favorable tolerability. The company plans a 12‑week 1 mpk cohort with potential extension, targeting a registrational strategy update in late 2026 and 12‑week data in early 2027. Additional GeneTAC programs include DT‑168 eye drops for FECD (Phase 2 biomarker trial, data expected 2027), DT‑818 for DM1 (Phase 1 MAD ongoing, data expected 2027), and preclinical candidates for Huntington’s disease.
Design Therapeutics, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, as it continues investing in its GeneTAC small-molecule pipeline. Research and development expenses were $14.4 million and general and administrative expenses were $5.3 million.
The company ended the quarter with $222.8 million in cash, cash equivalents and investment securities, which it believes will fund operations for more than 12 months. Design also raised $19.9 million of net proceeds by selling 2,006,550 shares through its at-the-market program. Key programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy and DT-818 for myotonic dystrophy type-1, with multiple clinical readouts anticipated from 2026 onward.
Design Therapeutics (DSGN) filed its Q3 10-Q, showing continued investment in its GeneTAC platform and clinical programs. Cash, cash equivalents and investment securities were $206.0 million as of September 30, 2025, and management states resources are sufficient for more than 12 months following issuance. Q3 operating expenses were $19.3 million (research and development $14.6 million; general and administrative $4.7 million), driving a Q3 net loss of $17.0 million. For the nine months, operating expenses totaled $61.3 million and net loss was $53.8 million.
The company is conducting the RESTORE-FA Phase 1/2 MAD trial of DT-216P2 in Friedreich ataxia and anticipates an update on FXN levels in the second half of 2026. In June 2025, the FDA placed a clinical hold on the DT-216P2 IND regarding the starting dose in the United States; the company plans to address the request. In FECD, Phase 2 biomarker data for DT-168 are anticipated in the second half of 2026. A third candidate, DT-818 for DM1, is cleared to begin a Phase 1 MAD trial in Australia in the first half of 2026.
As capital tools, a $300.0 million shelf (including an $100.0 million ATM) became effective in May 2025; no ATM sales occurred as of September 30, 2025. Common shares outstanding were 56,963,757 as of October 31, 2025.